In ovarian cancer, ALKBH5 promotes cisplatin resistance in cancer cells by modifying its m6A target gene JAK2 to activate the JAK2/STAT3 signaling pathway[21]. This evidence concerns the gene JAK2 and ovarian carcinoma.